• Regen BioPharma posted a net loss of $637,785 for the quarter ended June 30, 2026, widening 73.77% year over year.
• Revenue was $59,065, unchanged from the year-earlier quarter.
• Operating expenses fell to $34,536 from $99,821, led by lower consulting and professional fees of $20,694.
• Other expense deepened to $662,313 on derivative expense of $623,200.
• Cash was $239 at June 30, 2026; working capital deficit was about $5.9 million, with substantial doubt about going-concern status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regen BioPharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038576), on August 17, 2026, and is solely responsible for the information contained therein.